Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.

@article{Johansen2000AmphotericinBL,
  title={Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.},
  author={Helle Krogh Johansen and Peter C Gotzsche},
  journal={The Cochrane database of systematic reviews},
  year={2000},
  volume={3},
  pages={CD000969}
}
BACKGROUND Patients with cancer who are treated with chemotherapy or receive a bone marrow transplant have an increased risk of acquiring fungal infections. Such infections can be life-threatening. Antifungal drugs are therefore often given prophylactically to such patients, or when they have a fever. OBJECTIVES To compare the effect and adverse effects of AmBisome and other lipid soluble formulations of amphotericin B with conventional amphotericin B in cancer patients with neutropenia… CONTINUE READING